New Study Explores SCD Therapy's Potential to Combat Hyperinflammation in Severe Trauma Patients

Severe burns, inhalation injuries, and septicemia can trigger destructive hyperinflammation, leading to organ failure and death. A groundbreaking study, supported by a $2 million grant from the Department of Defense (DoD), is set to evaluate the effectiveness of SeaStar Medical's Selective Cytopheretic Device (SCD) therapy in addressing these life-threatening conditions. This research, a joint effort between SeaStar Medical and the Autonomous Reanimation and Evacuation (AREVA) Research Institute, aims to revolutionize treatment options for both military personnel and civilians suffering from severe trauma and infections.

The SCD therapy, which works in conjunction with continuous renal replacement therapy (CRRT), is designed to counteract hyperinflammation and aid in organ recovery. This innovative approach could potentially decrease the reliance on dialysis and save lives. Dr. Andriy Batchinsky, the principal investigator and founder of AREVA, has pointed out the study's potential to dramatically improve outcomes for patients with infection- and trauma-induced organ failures.

Operational support for the study will be provided by the Geneva Foundation, with research activities scheduled to begin in July 2025 at the AREVA Institute in San Antonio, Texas. The SCD therapy has already received FDA approval for treating pediatric acute kidney injury (AKI) and has demonstrated promising results in clinical trials, including a 50% reduction in mortality rates and shorter dialysis durations. SeaStar Medical is also exploring the therapy's application in treating adult AKI, highlighting its versatility across a range of acute and chronic conditions.

Dr. Kevin Chung, SeaStar Medical's chief medical officer, has underscored the significance of this study in assessing the SCD therapy's capacity to enhance recovery for critically injured service members. This initiative not only highlights the potential of SCD therapy to transform patient care but also represents a critical advancement in the search for innovative treatments for severe burn and trauma injuries. For more information on SeaStar Medical and their research, visit https://www.seastarmedical.com.